Effect of a Combination of Plant Extracts (BSL_EP024) on the Immune Response
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04029558 |
Recruitment Status :
Completed
First Posted : July 23, 2019
Last Update Posted : November 18, 2019
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Immune Response | Dietary Supplement: Combination of Plant Extracts (BSL_EP025) Dietary Supplement: Placebo | Not Applicable |
More than 90% of the diseases are related, directly or indirectly, with immune alterations. Traditionally, protection against infections and improvement of the immune response has been addressed by natural means through the use of plant extracts. This activity has been attributed to phenolic compounds.
The aim of the present study is to evaluate the effect of the combination of plant extracts (BSL_EP024) on immunological response parameters.
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 41 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) |
Primary Purpose: | Prevention |
Official Title: | Pilot Study of Nutritional Intervention, Randomized, Double Blind and Controlled Parallel Groups to Evaluate the Effect of the Consumption of the Combination of Plant Extracts (BSL_EP024) on the Immune Response in Adults |
Actual Study Start Date : | June 3, 2019 |
Actual Primary Completion Date : | July 3, 2019 |
Actual Study Completion Date : | July 3, 2019 |
Arm | Intervention/treatment |
---|---|
Experimental: Combination of plant extracts (BSL_EP024)
The volunteers will take two capsules daily with a combination of plant extracts (BSL_EP024)
|
Dietary Supplement: Combination of Plant Extracts (BSL_EP025)
Each participant will consume 2 capsules daily at lunch for 8 weeks. |
Placebo Comparator: Placebo
The volunteers will take two capsules daily with maltodextrin.
|
Dietary Supplement: Placebo
Each participant will consume 2 capsules daily at lunch for 8 weeks. |
- IgM [ Time Frame: 4 weeks ]Immunoglobulin M plasma levels
- IgA [ Time Frame: 4 weeks ]Immunoglobulin A plasma levels
- IgG [ Time Frame: 4 weeks ]Immunoglobulin G plasma levels
- IL-2 [ Time Frame: 4 weeks ]Plasma levels of interleukin-2
- IL-8 [ Time Frame: 4 weeks ]Plasma levels of interleukin-8
- TNF-alpha [ Time Frame: 4 weeks ]Plasma levels of tumor necrosis factor alpha

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 55 Years (Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Healthy adult between 18 and 55 years.
- Accept freely to participate in the study and sign the informed consent document.
Exclusion Criteria:
- Be under pharmacological treatments that may affect the immune response (anti-inflammatory drugs of chronic or frequent use, antiallergic treatments).
- Have allergy to some plant extracts
- Suffer from gastric problems or ulcers.
- Receive treatment with anticoagulant activity.
- Have a low expectation of adherence to the study protocol.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04029558
Spain | |
Biosearch Life | |
Granada, Andalucia, Spain, 18004 |
Study Chair: | Miguel Quesada, MD, PhD | Medical specialist in Endocrinology, Hospital San Cecilio de Granada |
Responsible Party: | Biosearch S.A. |
ClinicalTrials.gov Identifier: | NCT04029558 |
Other Study ID Numbers: |
C024 |
First Posted: | July 23, 2019 Key Record Dates |
Last Update Posted: | November 18, 2019 |
Last Verified: | July 2019 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Immune response Plant extracts Dietary supplement |